Company news
Elicio Therapeutics, Inc. (NASDAQ:ELTX) news
Elicio Therapeutics, Inc. news releases on 6ix. Latest, Sep 24, 2026: Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected…
Press releases & updates
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
September 24, 2026
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
August 31, 2026
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
August 24, 2026
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 13, 2026
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
August 10, 2026
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
July 6, 2026
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
July 2, 2026
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
June 29, 2026
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
June 17, 2026
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
June 15, 2026
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
June 1, 2026
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 11, 2026
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
April 30, 2026
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
March 12, 2026
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Elicio Therapeutics Reports Inducement Grants
January 16, 2026
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
December 11, 2025
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
November 19, 2025
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 13, 2025
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
November 7, 2025
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
November 3, 2025
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
October 27, 2025
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
September 29, 2025
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
September 17, 2025
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
August 12, 2025
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 7, 2025
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
August 5, 2025
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
June 17, 2025
Elicio Therapeutics Secures $10 Million in Financing
June 4, 2025
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 13, 2025
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
April 16, 2025
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
March 31, 2025
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
March 24, 2025